论文部分内容阅读
[目的]回顾性分析乳腺癌原发灶与转移灶中ER、PR、HER-2、COX-2表达的情况及临床意义。[方法]应用免疫组化的方法,检测了50例乳腺癌转移患者的ER、PR、HER-2、COX-2在原发灶与复发转移灶中的表达。[结果]乳腺癌原发灶与复发转移灶中ER阳性表达分别为70%和38%,有显著性差异(P=0.002)。PR、HER-2、COX-2在乳腺癌原发灶与复发转移灶中的表达差异无统计学意义(P>0.05)。原发灶与转移灶中HER-2与COX-2表达呈相关性(P<0.05)。[结论]乳腺癌原发灶和转移灶中ER、PR、HER-2、COX-2表达不一致,需根据转移灶受体的表达情况决定治疗方案。
[Objective] To retrospectively analyze the expression and clinical significance of ER, PR, HER-2 and COX-2 in primary and metastatic breast cancer. [Methods] The expression of ER, PR, HER-2 and COX-2 in primary breast cancer and recurrent metastasis of 50 breast cancer patients were detected by immunohistochemistry. [Results] The positive expression rates of ER in primary breast cancer and recurrent metastatic breast cancer were 70% and 38% respectively (P = 0.002). The expression of PR, HER-2 and COX-2 in primary breast cancer and recurrent metastatic breast cancer showed no significant difference (P> 0.05). The expression of COX-2 and HER-2 in primary tumor and metastasis were correlated (P <0.05). [Conclusion] The expressions of ER, PR, HER-2 and COX-2 in primary and metastatic breast cancer are not consistent. The treatment regimen should be decided according to the expression of metastatic receptor.